![]() Of note is that the primary vaccine made a difference to the immunogenicity of the various schedules: ‘It’s only through the inspiring efforts of the Com-COV2 participants and study teams that we can generate these data this will help get the world immunised against COVID-19 as quickly as possible.’ When it comes to cellular immunity, having a first dose of the Oxford-AstraZeneca vaccine followed by any of the other study vaccines generates a particularly robust response. ‘Encouragingly, all these schedules generated antibody concentrations above that of the licensed and effective two dose Oxford-AstraZeneca schedule. Professor Matthew Snape, Associate Professor in Paediatrics and Vaccinology at the University of Oxford, and Chief Investigator on the trial, said: ‘Thanks to studies such as these, we are now getting a more complete picture of how different COVID-19 vaccines can be used together in the same vaccine schedule. This study therefore supports flexible use of these vaccines in primary immunisation schedules, which is crucial to help rapid deployment of these vaccines, especially in low- and middle-income countries where vaccine supply may be inconsistent. No safety concerns were raised in this study of 1,070 participants, who took part in the study across nine National Institute for Health Research-supported sites. In a paper published in the Lancet, they report that participants receiving a first dose of Oxford-AstraZeneca or Pfizer-BioNTech generated a robust immune response when immunised nine weeks later with a second dose of COVID-19 vaccines manufactured by Novavax or Moderna. Pfizer-BioNTech/Novavax induced higher antibodies than two-dose Oxford-AstraZeneca schedule this schedule induced lower antibody and T-cell responses than two-dose Pfizer-BioNTech schedule.įollowing up first doses of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines with second doses of the Moderna or Novavax jabs will generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.Pfizer-BioNTech/Moderna induced higher antibody and T-cell responses than two-dose Pfizer-BioNTech schedule. ![]() ![]() Oxford-AstraZeneca followed by Moderna/Novavax schedules induced higher antibodies and T-cell responses than two-dose Oxford-AstraZeneca schedule. ![]() First dose of Oxford-AstraZeneca or Pfizer-BioNTech followed nine weeks later by second dose of Novavax or Moderna COVID-19 vaccines generated a robust immune response. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |